• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Magnesium Sulfate Post-Delivery Reduce Eclampsia Risk?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Vigil-DeGracia et al. (BJOG 2018) examined whether initial load and maintenance of MgS04 for a minimum of 8 hours before delivery requires another 24 hours of MgS04 post-delivery to reduce postpartum eclampsia

METHODS:

  • Randomized multicenter controlled trial (RCT)
    • MAG‐PIP (MAGnesium Postpartum In Preeclampsia) trial
    • Participants: Women with severe preeclampsia (severity criteria met >20 weeks gestation)
  • All women received 4 g loading dose followed by 1 g per hour for 8 hours as maintenance dose before delivery, then randomized to receive either
    • MgS04 continued for 24 hours postpartum
    • MgS04 Discontinued after delivery
  • Statistical analysis – calculated for a no-inferiority study
    • Using alpha error of 5% and power of 90%, the study required 511 women per group
  • Primary outcome
    • Incidence of eclampsia in the first 24 hours postdelivery
  • Secondary outcomes
    • Maternal death | Maternal complications (e.g., PPH, respiratory difficulty etc.) | Time to ambulation | Time to lactation

RESULTS:

  • 1,113 women were randomized
    • 555 patients MgS04 group | 558 no MgS04
    • Maternal characteristics similar between groups

Primary Outcome

  • There was no statistical difference in rate of eclampsia between groups
    • 0.18% in the MgS04 group vs 0.35% in the no MgS04 group
    • Relative Risk (RR) 0.7, 95% CI 0.1-3.3 (P=0.50)
    • 1 woman in the MgS04 group vs 2 women in the MgS04 group

Secondary Outcomes

  • No difference detected for total maternal complications
    • RR 1.0, 95% CI 0.8-1.2 (P = 0.76)
    • No differences detected for specific complications
  • Time to start ambulation was significantly shorter (6 hours) in the no MgS04 group
    • 18.1 ± 10.6 versus 11.8 ± 10.8 hours (P = 0.0001)
  • Time to start lactation was shorter (7 hours) in the no MgS04 group
    • 24.1 ± 17.1 versus 17.1 ± 16.8 hours (P = 0.0001)

CONCLUSION:

  • There is no benefit of continuing MgS04 administration postpartum to prevent eclampsia
    • Women in the no MgS04 group ambulated and started breastfeeding sooner
  • 50% of patients in both groups received antihypertensives postpartum
    • Not well understood but may impact eclampsia rates
  • Women with more complications were excluded, and these patients (e.g. with HELLP syndrome) should receive ongoing MgS04 postpartum
  • The authors caution due to sample size limitation
    • Power calculation was based on a higher eclampsia rate (2%) than observed in the study in the control group (0.35%)

Learn More – Primary Sources:

Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study.

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Eclampsia and Role of Magnesium Sulfate
Aspirin Treatment for Women at Risk for Preeclampsia – ACOG, SMFM and USPSTF Recommendations
Is Eclampsia in Pregnancy Linked with Greater Risk for Seizure Disorder?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site